Advertisement

Topics

FDA Grants Priority Review to Vertex’s Combination Therapy for Treatment of Cystic Fibrosis

13:52 EDT 24 Aug 2017 | Speciality Pharma Journal

BOSTON–(BUSINESS WIRE)–Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the acceptance of its applications for the use of the tezacaftor/ivacaftor combination treatment in people with cystic fibrosis (CF) ages 12 and older who have two copies of the F508del mutation or one F508del mutation and one residual function mutation that is responsive to tezacaftor/ivacaftor by the U.S. Food and Drug Administration

Original Article: FDA Grants Priority Review to Vertex’s Combination Therapy for Treatment of Cystic Fibrosis

NEXT ARTICLE

More From BioPortfolio on "FDA Grants Priority Review to Vertex’s Combination Therapy for Treatment of Cystic Fibrosis"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

Cystic Fibrosis
Affecting over 8,500 people in the UK, Cystic Fibrosis (CF) is one of the UK's most common life-threatening inherited diseases. Around half of the CF population can expect to live over 38 years, although improvements in treatments mean a baby born ...